

Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ

**Ref:** FOI-102024-0001159

**Date:** 15/10/2024

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000.

**Request**

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
- Aromatase Inhibitor as a single agent
- Atezolizumab
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Parp Inhibitors (Olaparib/Talazoparib)
- Pembrolizumab
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Trastuzumab deruxtecan
- Trastuzumab as a single agent or in combination
- Trastuzumab emtansine
- Any other active systemic anti-cancer therapy

Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

**Response**

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies.

<b><u>Drugs</u></b>	<b><u>Numbers of Patients</u></b>
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	43
Abemaciclib + Fulvestrant	7
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	30
Aromatase Inhibitor as a single agent	Not recorded in cEPMA system
Atezolizumab	2
Capecitabine as a single agent	15
Carboplatin + Paclitaxel	9
Eribulin as a single agent or in combination	19
Everolimus + Exemestane	3
Fulvestrant as a single agent	28
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	44
Palbociclib + Fulvestrant	3
Sacituzumab Govitecan	6
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	42
Transtuzumab deruxtecan	7
Trastuzumab as a single agent or in combination	95
Trastuzumab emtansine	16
Any other active systemic anti-cancer therapy	127

Q2. Does your Trust participate in any clinical trials for breast cancer? If so, [please provide the name of each trial, and the number of patients taking part.

Aspirin = < 5

**Please note that as per NHS Digital rules the Trust does not publish numbers lower than 5 as this could lead to the identification of the person(s) involved and cause distress to families and friends. The number of patients treated for breast cancer for the following drugs over the requested time period is less than 5, therefore, exemption Section 40(2) of the Freedom of Information Act has been applied.**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team  
The Dudley Group NHS Foundation Trust**